- Novel therapeutic options in prostate cancer before chemotherapy2013 | First Faculty of Medicine
- The importance of cooperation between urologist and oncologist in the treatment of castration-resistant prostate cancer2014 | First Faculty of Medicine
- The importance of cooperation between urologist and oncologist in the treatment of castration-resistant2014 | First Faculty of Medicine
- Prostate cancer - cardiac complications of treatment2021 | First Faculty of Medicine
- New treatment options in hormone-sensitive prostate cancer +12019 | First Faculty of Medicine
- Treatment of advanced prostate cancer2016 | First Faculty of Medicine
- Current treatment options for metastatic castration-resistant prostate cancer2018 | First Faculty of Medicine, Faculty of Physical Education and Sport, Faculty of Medicine in Hradec Králové
- Enzalutamide and abiraterone in the treatment of patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy2023 | First Faculty of Medicine
- Možnosti léčby karcinomu prostaty po selhání docetaxelu2015 | First Faculty of Medicine
- Role of the Urologist in the Treatment of Castration-Resistant Prostate Cancer in the Czech Republic2013 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Second Faculty of Medicine
- Innovation in the treatment of castration – resistant prostate cancer2012 | First Faculty of Medicine
- Radium-223 dichloride (Xofigo) - management of the treatment of castration-resistant prostate cancer2014 | Third Faculty of Medicine
- Role of the Urologist in the Treatment of Castration-Resistant Prostate Cancer in the Czech Republic2013 | Publication without faculty affiliation
- ARTA treatment of metastatic castration-resistant prostate cancer - case report2021 | First Faculty of Medicine
- New hormonal agents in castration-resistant prostate cancer2013 | First Faculty of Medicine
- Metastatic prostate cancer - changes in treatment strategy2019 | First Faculty of Medicine
- Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer The VIABLE Phase 3 Randomized Clinical Trial2022 | Faculty of Medicine in Hradec Králové